Comparison of plasma MicroRNA levels in drug naive, first episode depressed patients and healthy controls

Basit Öğe Kaydı
dc.contributor.authorCamkurt, Mehmet Akif
dc.contributor.authorAcar, Senel
dc.contributor.authorCoskun, Salih
dc.contributor.authorGunes, Mehmet
dc.contributor.authorGunes, Serkan
dc.contributor.authorYilmaz, Mehmet Fatih
dc.contributor.authorGorur, Aysegul
dc.date.accessioned2024-04-24T16:15:20Z
dc.date.available2024-04-24T16:15:20Z
dc.date.issued2015
dc.departmentDicle Üniversitesien_US
dc.description.abstractMajor depression is the most common psychiatric disorder. The diagnosis of depression depends on a patient's subjective complaints, and the nature of the heterogeneous disorder. Thus, there is no known biomarker for depression to date. Previous research has indicated that microRNAs are dysregulated in bipolar disorder and schizophrenia. We aimed to investigate microRNA dysregulation in plasma samples of patients with major depression. Venous blood samples of 50 depressed patients and 41 healthy controls were collected and the quantification of microRNAs was established using qRT-PCR. We found miR-320a significantly downregulated and miR-451a significantly upregulated in depressed patients. We also found miR-17-5p and miR-223-3p upregulated, but not as significantly as miR-451a. Merging our results with previous published data shows that the blood miR-320 family may be a potential microRNA family dysregulated in major depression. Research should be performed on miR-320-related pathways and their relationship to depression. Additionally, miR-451a could serve as a candidate biomarker for depression based on the acting mechanism of ketamine. Studies targeting miR-451a levels before and after treatment could be helpful. (C) 2015 Elsevier Ltd. All rights reserved.en_US
dc.description.sponsorshipMersin University BAP commission [BAP-TF (MAC) 2014-3 TU]en_US
dc.description.sponsorshipWe thank to Mersin University BAP commission for funding our research Project number: BAP-TF (MAC) 2014-3 TU.en_US
dc.identifier.doi10.1016/j.jpsychires.2015.07.023
dc.identifier.endpage71en_US
dc.identifier.issn0022-3956
dc.identifier.issn1879-1379
dc.identifier.pmid26343596
dc.identifier.scopus2-s2.0-84940846726
dc.identifier.scopusqualityQ1
dc.identifier.startpage67en_US
dc.identifier.urihttps://doi.org/10.1016/j.jpsychires.2015.07.023
dc.identifier.urihttps://hdl.handle.net/11468/15763
dc.identifier.volume69en_US
dc.identifier.wosWOS:000361927800010
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofJournal of Psychiatric Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBlooden_US
dc.subjectPlasmaen_US
dc.subjectMicrornaen_US
dc.subjectDepressionen_US
dc.subjectComparisonen_US
dc.subjectGeneen_US
dc.titleComparison of plasma MicroRNA levels in drug naive, first episode depressed patients and healthy controlsen_US
dc.titleComparison of plasma MicroRNA levels in drug naive, first episode depressed patients and healthy controls
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu